It's been a month since the Master Investor Show, and it's been a busy one. Markets have basically gone nowhere, except for the post-Macron relief rally which, if you ask me, will soon peter out. I've been busy getting the Juvenescence book done, and I think I am now about 70% of the way there. It's a tough, but worthwhile, subject; and though it's behind schedule, we will all have so much more of it because of longevity. A month's delay is but a blink of the eye! The book will showcase three portfolios for those interested in investing in the area of longevity, each tailored to different risk appetites. With nearly one fifth of US GDP devoted to healthcare, most of it spent in the last two years of people's lives, something has to be found to reduce the burden of disease in the elderly. Two thirds of all deaths are the result of cardiovascular disease, neurodegenerative disease, diabetes and cancer; there is good news in abundance for three of these, and somewhat halting and disappointing progress in the area of dementia. | |
Ingen kommentarer:
Send en kommentar